Sclerostin is a direct target of osteoblast-specific transcription factor osterix.
Osterix (Osx) is an osteoblast-specific transcription factor required for osteoblast differentiation and bone formation. Osx knock-out mice lack bone completely. Recent findings that Osx inhibits Wnt signaling provide a feedback control mechanism involved in bone formation. Mechanisms of Osx inhibition on Wnt signaling are not fully understood. Our results in this study revealed that the expression of a Wnt antagonist Sclerostin (Sost) was downregulated in Osx-null calvaria. Overexpression of Osx in stable C2C12 mesenchymal cell line resulted in Sost upregulation. Transient transfection assay showed that Osx activated 1kb Sost promoter reporter activity in a dose-dependent manner. To define Sost promoter activated by Osx, we made a series of deletion mutants of Sost constructs, and narrowed down the minimal region to the proximal 260bp. Gel shift assay indicated that Osx bound to GC-rich site within this minimal region, and that point mutations of this binding site disrupted Osx binding. Moreover, the same point mutations in 260bp Sost promoter reporter disrupted the promoter activation by Osx, suggesting that the GC-rich binding site was responsible for Sost promoter activation by Osx. To further examine physical association of Osx with Sost promoter in vivo, Chromatin immunoprecipitation (ChIP) assays were performed using primary osteoblasts from mouse calvaria. Osx was found to associate with endogenous Sost promoter. Taken together, these findings support our hypothesis that Sost is a direct target of Osx. This provides a new additional mechanism through which Osx inhibits Wnt signaling during bone formation.
Yang
Fan
F
Bone Research Laboratory, Texas Scottish Rite Hospital for Children, Dallas, TX 75219, USA.
Tang
Wanjin
W
So
Sarah
S
de Crombrugghe
Benoit
B
Zhang
Chi
C
D048868:Adaptor Proteins, Signal Transducing; D000818:Animals; D001665:Binding Sites; D019485:Bone Morphogenetic Proteins / Q000235:genetics*; D002460:Cell Line; D015536:Down-Regulation; D005819:Genetic Markers / Q000235:genetics*; D006023:Glycoproteins; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D051379:Mice; D008817:Mice, Mutant Strains; D010006:Osteoblasts / Q000378:metabolism*; D011401:Promoter Regions, Genetic; D000076182:Sp7 Transcription Factor; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism*; D014158:Transcription, Genetic; D015533:Transcriptional Activation
D048868:Adaptor Proteins, Signal Transducing; D019485:Bone Morphogenetic Proteins; D005819:Genetic Markers; D006023:Glycoproteins; D036341:Intercellular Signaling Peptides and Proteins; C486030:Sost protein, mouse; D000076182:Sp7 Transcription Factor; C479466:Sp7 protein, mouse; D014157:Transcription Factors
J Biol Chem. 2005 Jul 22;280(29):26770-5
15908424
Dev Cell. 2005 May;8(5):739-50
15866164
J Biol Chem. 2001 Nov 2;276(44):40614-20
11514567
Am J Hum Genet. 2002 Jan;70(1):11-9
11741193
HSS J. 2008 Feb;4(1):66-70
18751865
J Bone Miner Res. 2003 Jun;18(6):960-74
12817748
J Biol Chem. 2003 Sep 12;278(37):35325-36
12840015
Cell. 2002 Jan 11;108(1):17-29
11792318
Genes Dev. 1999 Aug 15;13(16):2072-86
10465785
Development. 2005 Jan;132(1):49-60
15576404
Curr Top Dev Biol. 2006;76:103-27
17118265
Arch Biochem Biophys. 2008 May 15;473(2):112-6
18364235
EMBO J. 2003 Dec 1;22(23):6267-76
14633986
Development. 2006 Aug;133(16):3231-44
16854976
Proc Natl Acad Sci U S A. 2008 May 13;105(19):6936-41
18458345
J Bone Joint Surg Am. 2008 Feb;90 Suppl 1:31-5
18292354
J Clin Invest. 2006 May;116(5):1202-9
16670761
Calcif Tissue Int. 2008 Jun;82(6):445-53
18521528
Cells Tissues Organs. 2009;189(1-4):144-52
18728356
Cell. 1997 May 30;89(5):755-64
9182763
Bone. 2005 Aug;37(2):148-58
15946907
J Exp Med. 2004 Mar 15;199(6):805-14
15024046
J Clin Endocrinol Metab. 2003 Dec;88(12):5778-83
14671168
Dev Cell. 2005 May;8(5):727-38
15866163
J Bone Miner Res. 2009 Oct;24(10):1651-61
19419300